Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases

Area of Science:

• Biotechnology
• Immunology
• Drug Discovery

Background:

• Antigen-specific B cell screening is crucial for biotherapeutic development.
• Conventional methods like hybridoma technology and single B cell screening are established but can be time-consuming.
• Recent demands, particularly for infectious diseases, necessitate faster and more efficient antibody discovery.

Purpose of the Study:

• To provide an overview of conventional and emerging single B cell screening approaches.
• To highlight the strengths and weaknesses of different screening methods.
• To detail the impact of innovative technologies on monoclonal antibody discovery.

Main Methods:

• Review of established techniques (hybridoma, conventional single B cell screening).
• Analysis of emergent single B cell screening approaches.
• Examination of enabling technologies: miniaturization, microfluidics, multiplexing, deep sequencing.

Main Results:

• Technological advancements have significantly increased throughput and reduced labor in single B cell screening.
• Innovative technologies facilitate the rapid identification of monoclonal antibodies with specific properties.
• The COVID-19 pandemic spurred the development and application of advanced antibody discovery methodologies.

Conclusions:

• Emergent single B cell screening methods offer enhanced efficiency and speed.
• Innovative technologies are critical for discovering broadly neutralizing antibodies against infectious diseases.
• Advanced antibody discovery is vital for addressing diverse pathological conditions and future pandemics.